Carl Zeiss Meditec (AFX) PT Set at €60.00 by Nord/LB
Carl Zeiss Meditec (ETR:AFX) has been given a €60.00 ($71.43) target price by research analysts at Nord/LB in a report released on Tuesday. The firm currently has a “buy” rating on the stock. Nord/LB’s price objective would indicate a potential upside of 14.26% from the stock’s previous close.
AFX has been the topic of a number of other reports. Independent Research set a €54.00 ($64.29) target price on shares of Carl Zeiss Meditec and gave the company a “neutral” rating in a research note on Friday. Commerzbank set a €42.00 ($50.00) price target on shares of Carl Zeiss Meditec and gave the stock a “neutral” rating in a research report on Friday. Berenberg Bank set a €48.00 ($57.14) price target on shares of Carl Zeiss Meditec and gave the stock a “buy” rating in a research report on Friday. Deutsche Bank set a €40.00 ($47.62) price objective on shares of Carl Zeiss Meditec and gave the stock a “neutral” rating in a report on Friday, December 1st. Finally, set a €52.00 ($61.90) price target on shares of Carl Zeiss Meditec and gave the company a “buy” rating in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of €49.21 ($58.59).
Carl Zeiss Meditec (ETR:AFX) opened at €52.51 ($62.51) on Tuesday. Carl Zeiss Meditec has a 1-year low of €31.44 ($37.43) and a 1-year high of €52.83 ($62.89).
Carl Zeiss Meditec AG operates as a medical technology company worldwide. It operates through Ophthalmic Devices and Microsurgery segments. The Ophthalmic Devices segment offers optical biometers, ophthalmic microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Receive News & Ratings for Carl Zeiss Meditec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec AG and related companies with MarketBeat.com's FREE daily email newsletter.